Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

ADMA Biologics ADMA G&A

Discontinued — last reported Q1 '21

G&A at other companies

AnaptysBio, Inc.ANAB

$26.2M+85.4%

ZymeworksZYME

$15.07M-11.3%

Apogee Therapeutics, Inc.APGE

$21.95M+31.4%

BiohavenBHVN

$26.6M-21.7%

Adaptive BiotechnologiesADPT

$20.98M+20.6%

Aurinia PharmaceuticalsAUPH

$22.03M+8.3%

Segments

By segment

See full

ADMA Bio Manufacturing$8.46M-0.4%

Plasma Collection Centers$0—

Other financials

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

See full

Market cap$2.02B-54.5%

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: ADMA Biologics’s 10-Q, filed May 12, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.